Treatment News : ARVs Reduce Risk of Death After Lymphoma Diagnosis

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » July 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

July 9, 2013

ARVs Reduce Risk of Death After Lymphoma Diagnosis

The risk of death from HIV-related lymphoma is associated with a higher cumulative viral load during the first six months after diagnosis with the cancer, supporting the argument for early antiretroviral (ARV) intervention, aidsmap reports. Publishing their findings in the online edition of the journal AIDS, investigators culled the records of more than 25,000 people receiving care for HIV between 1996 and 2011 and identified 224 who were diagnosed with lymphoma. All members of the group were still living six months after their lymphoma diagnosis and had received at least two viral load screens during that period.

The median overall viral load at the time of the lymphoma diagnosis was about 10,000, with a third of the study group undetectable.

At the outset of the study, 47 percent were taking ARVs. Three months following the lymphoma diagnosis, 58 percent were taking HIV therapy, a figure that increased to 71 percent six months after the diagnosis.

About two-thirds of the group survived until the end of the five-year study period. At this time, 54 percent of those who had a cumulative six-month viral load greater than the median of the study group (above 10,000) were still living. Seventy percent of those who had a cumulative viral load below the median (less than 10,000) during the six months following their lymphoma diagnosis survived five years.

For each power of 10 increase in cumulative viral load (for example: from 10 to 100, or 10,000 to 100,000) during the first six months following the lymphoma diagnosis, there was a 35 percent increase in risk of death in the period spanning the six-month mark and the end of the fifth year.

The viral load at the time participants received their lymphoma diagnosis was not associated with the risk of death.

To read the aidsmap story, click here.

To read the abstract, click here.

Search: Lymphoma, HIV, antiretrovirals, viral load, AIDS, risk of death, mortality risk.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Hide comments

Previous Comments:


         


[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Are you buying holiday gifts that raise HIV/AIDS awareness?
Yes
No

Survey
Smoke Signals

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.